Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Metastatic Non-small Cell Lung Cancer
Clinical trial register · United States · industry-sponsored

Metastatic Non-small Cell Lung Cancer Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 14 Florida 11 Arizona 9 Illinois 9 Colorado 8
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Metastatic Non-small Cell Lung Cancer trials in the USA

17 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07154290Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
Regeneron Pharmaceuticals
Phase 2
300
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Illinois, Indiana
2026-03-18
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
California, Colorado, Illinois, Michigan, New York, Ohio, Pennsylvania, Texas
2025-12-17
Active, closed
AstraZeneca
Phase 3
768
Arkansas, California, Florida, Missouri, New York, Ohio, Pennsylvania, Tennessee
2024-10-04
Recruiting
NovoCure GmbH
Phase 3
734
Alabama, Arizona, California, Florida, Illinois, Indiana, Kansas, Missouri
2024-07-31
Recruiting
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
NCT06343402Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
350
Alabama, California, Colorado, Connecticut, Illinois, Kansas, Maryland, Michigan
2024-05-22
Active, closed
AstraZeneca
Phase 3
895
Arkansas, California, Colorado, Florida, Indiana, Iowa, Maryland, Michigan
2023-10-24
Active, closed
ArriVent BioPharma, Inc.
Phase 3
398
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Illinois, Indiana
2023-06-01
Active, closed
BeiGene
Phase 2
400
California, Massachusetts, New York, Oregon, Texas
2023-03-07
Active, closed
Daiichi Sankyo
Phase 3
1,170
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland
2023-01-11
Active, closed
ArriVent BioPharma, Inc.
Phase 1
160
Arizona, California, Florida, Michigan, Texas, Virginia
2022-06-30
Active, closed
Daiichi Sankyo
Phase 3
740
Arizona, California, Colorado, Maryland, Massachusetts, New Hampshire, New Jersey, New York
2022-03-04
Recruiting
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
NCT04614103Metastatic Non Small Cell Lung Cancer
Iovance Biotherapeutics, Inc.
Phase 2
170
Arizona, Florida, Illinois, Kentucky, Maryland, Michigan, Minnesota, Nebraska
2021-05-07
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
California, Colorado, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky
2021-02-23
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2020-12-02
Active, closed
Eli Lilly and Company
Phase 3
545
California, Colorado, Hawaii, Kansas, New York, North Carolina, Pennsylvania
2015-05-06
Rows per page Showing 1–17 of 17
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/metastatic-non-small-cell-lung-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 17 of those studies listing the condition Metastatic Non-small Cell Lung Cancer.

How many Metastatic Non-small Cell Lung Cancer trials are recruiting in the US?

6 of the 17 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 11 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Metastatic Non-small Cell Lung Cancer), 17 studies
PhaseStudiesRecruitingShare
Phase 310258.8%
Phase 23217.6%
Phase 12111.8%
Observational105.9%
Phase 2/3115.9%

Most active sponsors

Lead sponsors with the most studies (Metastatic Non-small Cell Lung Cancer)
Lead sponsorStudiesRecruiting
ArriVent BioPharma, Inc.31
AstraZeneca20
Daiichi Sankyo20
Mirati Therapeutics Inc.21
BeiGene10
Bristol-Myers Squibb10
Eli Lilly and Company10
Iovance Biotherapeutics, Inc.11
Merck Sharp & Dohme LLC10
NovoCure GmbH11

Top states

Top states (Metastatic Non-small Cell Lung Cancer), by number of studies with a site there
StateStudies
California14
Florida11
Arizona9
Illinois9
Colorado8
Indiana6
Alabama5
Maryland5
Michigan5
New York5
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.